media – Page 20 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing

According to the Medicine Intelligence Data Investment Pattern Database, Yangqi Medical Chip, committed to becoming a pioneer in precision nuclear medicine, recently announced the completion of tens of millions of yuan in PreA round financing. This round of financing is led by Anfeng Venture Capital, and the raised funds will mainly be used for market promotion of approved products, approval of new product research and development, and expansion of the pet radiotherapy market. Yangqi Medical Core was established in 2021, and its core founding team is composed of clinical experts in nuclear medicine, nuclear physics and artificial intelligence, tumor radiotherapy, and radiation physics from Stanford, Alibaba, and other domestic and foreign institutions. The company is headquartered in Shenzhen and has research and development centers in Hangzhou and Shanghai. It is reported that Yangqi Medical Core is deeply involved in the fields of nuclear medicine and tumor radiation therapy. In response ...
- Source: drugdu
- 65
- November 21, 2024
Endovascular stent approved through priority green channel

Recently, the Equipment Review Center of the National Medical Products Administration released the results of the priority approval application for medical devices (No. 14 of 2024), and Shanghai Qigong Medical Technology Co., Ltd. (hereinafter referred to as Qigong Medical)’s product – endovascular stent – passed the priority approval green channel. It is worth mentioning that this product is urgently needed in clinical practice and there are no registered medical devices of the same variety in China. Qigong Medical focuses on innovative vascular intervention products Against the backdrop of an aging population, the incidence of cardiovascular diseases in China continues to rise, with high mortality rates, difficult treatment, and high risks associated with aortic disease. At present, the clinical treatment options for aortic diseases in China mainly include surgical open treatment and endovascular intervention treatment. Endovascular intervention therapy is a rapidly developing clinical treatment technique in recent years, which combines a ...
- Source: drugdu
- 77
- November 21, 2024
Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified

On November 14, the Shanxi Provincial Drug and Equipment Centralized Bidding and Procurement Center issued the “Notice on the Adjustment and Disposal of the Price of the Centralized Procurement of Amoxicillin and Other Drugs in the Guangdong Alliance” (hereinafter referred to as the “Notice”). It is worth noting that there are still 11 manufacturers and 20 specifications that refuse to reduce prices for rectification, including well-known pharmaceutical companies, including AstraZeneca, Sanofi, Eli Lilly and other foreign pharmaceutical companies, and their products include well-known brand drugs such as Plavix (clopidogrel bisulfate tablets), Iressa (gefitinib tablets), and Alimta (pemetrexed disodium for injection). The “Notice” emphasizes that the relevant drugs that refuse to accept the price rectification requirements will be disqualified from being selected and the selected price will be disqualified, and will be transferred to the alternative catalog. The platform will increase price risk warnings, and the task volume of the centralized ...
- Source: drugdu
- 85
- November 21, 2024
EMA recommends approval of Lencanermab

After four months of deliberation, the European Medicines Agency (EMA) has “changed its mind” on Lencanermab. On November 14, the EMA Committee for Medicinal Products for Human Use (CHMP) announced that after re-examining Lencanermab, it recommended approval of Lencanermab for the treatment of mild cognitive impairment or mild dementia caused by Alzheimer’s disease, suitable for apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers. According to regulations, the European Commission is expected to make a final ruling on the marketing authorization application for Lencanermab within the next 67 days. Of course, the European Commission is not in a good position to raise objections, so it is equivalent to approval. Although we had expected this result four months ago, it can be imagined that there were a lot of discussions in the middle. Foreign media commented that “EMA’s attitude towards Lencanermab has reversed 180 degrees.” This time, after Eisai/Biogen submitted the subgroup ...
- Source: drugdu
- 65
- November 21, 2024
AstraZeneca’s new dual anti-cancer drug approved for clinical trials in China

On November 15, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that AstraZeneca’s Class 1 new drug AZD0486 was approved for two clinical trials with implicit approval, which are intended to be used for the treatment of previously untreated follicular lymphoma in adults; and relapsed and refractory follicular lymphoma in adults who have received at least 2 lines of systemic treatment or more. Public information shows that AZD0486 is a CD19/CD3-targeted bispecific T cell adaptor protein under development by AstraZeneca, which is a next-generation T cell adaptor. This is the first time that a drug has been approved for clinical trials in China for the indication of follicular lymphoma (FL). In a clinical study recently published by AstraZeneca, the product showed an overall response rate (ORR) of up to 96% when used to treat patients with relapsed/refractory FL (R/R FL). ...
- Source: drugdu
- 76
- November 21, 2024
Novo Nordisk’s weekly weight loss formulation is officially launched

On November 17, Novo Nordisk announced that its weekly formulation of glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide (trade name: Novowin) for long-term weight management was officially launched in China, providing a weight loss option for Chinese overweight and obese patients. It is understood that with the official commercialization of Novowin, the first prescription of semaglutide for weight loss indications in public hospitals will be issued in Shanghai next week. Regarding the pricing of Novowin, Novo Nordisk responded: “We have begun to apply for Novowin provincial bidding network, and the sales price will refer to the provincial online price.” Previously, Novo Nordisk’s semaglutide for the treatment of type 2 diabetes, Novotai, has been included in the medical insurance, and the cost of a 3 ml dose is less than 800 yuan. In addition, Novowin has previously entered the private hospital channel and can be booked through the Internet platform, with a ...
- Source: drugdu
- 92
- November 21, 2024
Medical Philippines

Organiser：Philippine Medical Association, Fireworks Exhibitions Singapore Time：August 13-15, 2025 Address：Seashell Ln, Pasay, 1300 Metro Manila, Philippines Exhibition hall：SMX Convention Center Manila Product range: Medical Devices & Equipment: Medical Assistive Devices, Diagnostic Equipment, Monitoring Equipment, Therapeutic Equipment, Laboratory & Analytical Equipment, Surgical Special Equipment, Sterilization Equipment, Traction & Orthopedic Devices, Rehabilitation & Physical Therapy Equipment, Medical Vehicles, Beds, Tables, Emergency & Rescue Equipment, Surgical Equipment, Diagnostic Supplies & Equipment, Analysis & Control, Monitoring Devices, Surgical Instruments, Preventive Medicine Equipment, Ophthalmic Instruments & Equipment, ENT Equipment, Dental Supplies & Equipment, Radiological Medical Equipment, Medical Reagents & Equipment, Prostheses & Rehabilitation Equipment, Medical Healthcare Products & Equipment, Medical Assistive Devices, Diagnostic Equipment, Therapeutic Equipment, Laboratory & Analytical Equipment, etc. Medical Institutions & Laboratory Technology Equipment: Laboratory Instruments & Equipment, Laboratory Furniture, Laboratory Automation & Accessories, Optical Instruments & Equipment, Medical Laboratory Analysis & Diagnostic Instruments, Biopharmaceutical Instruments, Cellular Biology Instruments, Biotechnology Equipment, ...
- Source: drugdu
- 104
- November 21, 2024
Commercial raw liquid and formulation workshop of Altruist Biologics ADC has been officially put into operation

On November 15, 2024, Altruist Biologicstech, a leading domestic biopharmaceutical CDMO company, announced that its antibody conjugated drug (ADC) raw liquid and formulation production workshop (M3) located at its Hangzhou production base has officially started production! Becoming one of the few companies in China that can provide one-stop services from antibody and antibody conjugate drug stock solutions to formulations. This powerful production capacity will be able to meet the growing demand for ADC drugs in the market, accelerate the process of partner product launch, and enhance competitiveness. On that day, Altruist Biologicstech Hangzhou Base welcomed a visiting delegation composed of outstanding founders and executives from the domestic biopharmaceutical industry, who visited the ADC commercial raw material and preparation workshop, as well as four 20000 liter antibody raw material factories and preparation factories. The delegation expressed high interest and appreciation for the design layout, advanced hardware facilities, and automated production lines ...
- Source: drugdu
- 77
- November 20, 2024
Barco showcases new products at CCR2024, adding momentum to precision medicine

The 31st Radiology Academic Conference of the Chinese Medical Association (CCR2024) was held at the Shanghai World Expo Center from November 14th to 17th. Barco showcased its new Coronis OneLook 32MP multimodal diagnostic imaging display, integrated reading center, and multiple radiology displays at the booth, bringing cutting-edge technology and outstanding products to the Chinese precision medicine market with updated and more comprehensive solutions. New product One Look 32MP unveiled, showcasing higher standards in the medical display field The display is a bridge connecting radiologists and medical imaging, and its performance directly affects the accuracy of doctors’ capture, interpretation, and diagnosis of image details. At this conference, Barco unveiled its new Coronis OneLook 32MP multimodal fusion display, bringing more refined solutions to the Chinese medical market. The Coronis OneLook 32MP multimodal fusion display is Barco’s industry-leading medical display solution, featuring a 32MP ultra high definition resolution and a 33 inch large ...
- Source: drugdu
- 80
- November 20, 2024
【EXPERT Q&A】How to determine the clinical evaluation path of medical devices?

Drugdu.com expert’s response: The clinical evaluation pathway for medical devices is a crucial process for assessing their safety and effectiveness, determining their suitability for market release and clinical use. Below are the general steps and considerations for determining the clinical evaluation pathway for medical devices: Ⅰ. General Steps Clarify Product Characteristics and Scope of Application: Understand the basic principles, structural composition, manufacturing materials, and intended use of the medical device. First, confirm the scope of application of the product to facilitate targeted clinical evaluation. Assess Clinical Risks and Existing Clinical Data: Analyze potential adverse events or risks associated with the product during use. Evaluate whether sufficient clinical data exist to support the safety and effectiveness of the product. Select Clinical Evaluation Pathway: Based on product characteristics, clinical risks, and existing clinical data, select the most suitable clinical evaluation pathway. Ⅱ. Considerations Inclusion in the “Catalogue of Medical Devices Exempt from ...
- Source: drugdu
- 84
- November 20, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.